rolofylline has been researched along with furosemide in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, A; Karasawa, A; Kawakita, T; Kubo, K; Mizumoto, H; Nonaka, H; Shimada, J; Suzuki, F | 1 |
| Karasawa, A; Kusaka, H; Nagashima, K | 2 |
| Karasawa, A; Kobayashi, T; Kusaka, H; Yamagata, T | 1 |
| Karasawa, A; Kusaka, H; Sato, K; Yao, K | 1 |
| Karasawa, A; Kusaka, H; Sano, J; Sato, K; Yao, K | 1 |
| Karasawa, A; Kusaka, H | 1 |
| Karasawa, A; Kobayashi, T; Mizumoto, H | 1 |
| Karasawa, A; Kusaka, H; Nagashima, K; Sato, K | 1 |
| Karasawa, A; Kusaka, H; Nagashima, K; Nomura, H | 1 |
| Abe, Y; Aki, Y; Kimura, S; Kiyomoto, K; Nishiyama, A; Tomohiro, A | 1 |
| Ina, Y; Karasawa, A; Nagashima, K; Ohno, T; Yao, K | 1 |
| Dittrich, HC; Fields, TK; Givertz, MM; Massie, BM; Pearson, LL | 1 |
| Gottlieb, SS | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Gheorghiade, M; Givertz, MM; Hillege, HL; Metra, M; O'Connor, CM; Ponikowski, P; Subacius, H; Teerlink, JR; Ter Maaten, JM; Valente, MA; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
1 review(s) available for rolofylline and furosemide
| Article | Year |
|---|---|
Adenosine A1 antagonists and the cardiorenal syndrome.
Topics: Adenosine A1 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Kidney Function Tests; Male; Mice; Prognosis; Randomized Controlled Trials as Topic; Receptor, Adenosine A1; Risk Assessment; Severity of Illness Index; Syndrome; Treatment Outcome; Xanthines | 2008 |
3 trial(s) available for rolofylline and furosemide
| Article | Year |
|---|---|
The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Topics: Aged; Creatinine; Diuresis; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Renal Insufficiency; Sodium; Treatment Outcome; Xanthines | 2007 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Patient Readmission; Renal Insufficiency; Sulfonamides; Torsemide; Treatment Outcome; Weight Loss; Xanthines | 2014 |
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Decision Support Techniques; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Patient Readmission; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2016 |
12 other study(ies) available for rolofylline and furosemide
| Article | Year |
|---|---|
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
Topics: Acute Kidney Injury; Adenosine; Animals; Cations, Monovalent; Diuretics; Male; Potassium; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, Purinergic; Sodium; Structure-Activity Relationship; Xanthines | 1992 |
Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats.
Topics: Animals; Ascites; Diuretics; Edema; Furosemide; Male; Nephrosis; Purinergic P1 Receptor Antagonists; Puromycin Aminonucleoside; Rats; Rats, Wistar; Sodium Chloride Symporter Inhibitors; Trichlormethiazide; Xanthines | 1995 |
Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats.
Topics: Absorption; Acute Kidney Injury; Administration, Oral; Animals; Blood Urea Nitrogen; Cisplatin; Creatinine; Disease Models, Animal; Furosemide; Glomerular Filtration Rate; Injections, Intravenous; Kidney Tubules; Male; Potassium; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Renal Circulation; Sodium; Trichlormethiazide; Water; Xanthines | 1995 |
Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in anesthetized dogs.
Topics: Anesthesia; Animals; Diuretics; Dogs; Electrolytes; Female; Furosemide; Glomerular Filtration Rate; Hemodynamics; Male; Purinergic P1 Receptor Antagonists; Renal Circulation; Trichlormethiazide; Urodynamics; Xanthines | 1994 |
Protective effects of KW-3902, a novel adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Disease Models, Animal; Furosemide; Gentamicins; Injections, Subcutaneous; Kidney; Male; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Trichlormethiazide; Xanthines | 1994 |
Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in various models of acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Disease Models, Animal; Diuresis; Furosemide; Male; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Xanthines | 1994 |
Effects of repeated administration of KW-3902, a novel adenosine A1-receptor antagonist, on its pharmacological actions.
Topics: Acute Kidney Injury; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Administration, Oral; Animals; Diuretics; Furosemide; Glycerol; Heart Rate; Male; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Trichlormethiazide; Urination; Xanthines | 1993 |
Diuretic effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a novel adenosine A1 receptor antagonist, in conscious dogs.
Topics: Animals; Diuretics; Dogs; Female; Furosemide; Purinergic P1 Receptor Antagonists; Trichlormethiazide; Xanthines | 1993 |
Effects of KW-3902, a novel adenosine A1-receptor antagonist, on cephaloridine-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Cephaloridine; Diuretics; Electrolytes; Furosemide; Male; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Trichlormethiazide; Xanthines | 1994 |
Antihypertensive effects of KW-3902, an adenosine A1-receptor antagonist, in Dahl salt-sensitive rats.
Topics: Animals; Diet; Diuretics; Dose-Response Relationship, Drug; Furosemide; Hypertension; Male; Purinergic P1 Receptor Antagonists; Rats; Rats, Inbred Strains; Time Factors; Trichlormethiazide; Xanthines | 1995 |
Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs.
Topics: Adenosine; Anesthesia; Animals; Diuretics; Dogs; Female; Furosemide; Hemodynamics; Kidney; Male; Purinergic P1 Receptor Antagonists; Urination; Vasoconstriction; Xanthines | 1997 |
Effect of the selective adenosine A1-receptor antagonist KW-3902 on lipopolysaccharide-induced reductions in urine volume and renal blood flow in anesthetized dogs.
Topics: Animals; Blood Pressure; Diuresis; Diuretics; Dogs; Female; Furosemide; Heart Rate; Lipopolysaccharides; Male; Oliguria; Purinergic P1 Receptor Antagonists; Renal Circulation; Xanthines | 2000 |